Biotech Co. Revance Faces Suit After Tender Offer Weakens
By Emilie Ruscoe · January 6, 2025, 7:42 PM EST
Biotechnology company Revance Therapeutics Inc. and two of its executives face a proposed investor class action alleging the company hurt investors after the value of a take-private tender offer was negotiated...
To view the full article, register now.